VIM and glioblastoma: Antibodies that bind to cell-surface VIM have been effectively used to detect CTCs in patients with gastric cancer [132,133], sarcoma [134,135], glioblastoma [131], neuroblastoma [136], hepatocellular carcinoma [137], breast cancer [138], prostate cancer [139], and lung cancer [140].